Press Releases

SALT LAKE CITY, Sept. 1, 2026 /CNW/ -- USANA Health Sciences (NYSE:USNA) Chairman and CEO Kevin Guest is calling on people to make service a more intentional part of their lives with a challenge: find someone who needs help, then act. The invitation reflects what Guest calls The Holland Principle in his book, All The Right Reasons: 12 Timeless Principles for Living a Life in Harmony: "Find opportunities to serve, then act.""No matter how unexceptional we think we are, each of us has a great capacity to help others, to make someone's life better," said Guest.Guest developed the principle during volunteer missionary service in th

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, which is being held Sept. 14–16, 2026, in New York, NY.Management’s fireside chat is scheduled for Tuesday, Sept. 15, at 7:45 am ET. A live audio webcast of the session can be accessed here.An archived replay of the session will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.About NeoGenomicsNeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We off

PLEASANTON, Calif., Sept. 1, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced Veeva Falcon Safety, an agentic safety operations product to streamline adverse event intake, case processing, and follow-up to reduce costs, increase speed, and maintain compliance for biopharma companies of all sizes. In addition to working seamlessly with Veeva Safety, Falcon Safety will provide intake and follow-up management for any E2B-compliant safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance."We've had the privilege of working closely with case processors, pharmacovigilance experts, and safety specia

First sailboat autopilot to use brushless linear actuator with built-in ECU for superior performance, reliability and simplified installationOLATHE, Kan., Sept. 1, 2026 /PRNewswire/ -- Garmin (NYSE:GRMN), the world's largest1 and most innovative marine electronics manufacturer, today announced SmartDrive™, a ground-breaking autopilot system that leverages a brushless linear actuator, built-in ECU and a rudder feedback sensor for improved durability and long-term reliability. Designed for sailboats and catamarans up to 45 feet (maximum displacement of 33,000 pounds), the Reactor 40 Corepack with SmartDrive provides top-tier autopilot performance with up to 1,050 pounds of maximum thrust, help

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and eligibility for accelerated approval and priority reviewPhase 3 design fully aligned with FDA; Biologics License Application (BLA) filing anticipated in 2028OCU410 is designed as a one-time subretinal gene therapy that addresses multiple disease pathways, offering a differentiated approach from approved complement inhibitors in the U.S. which address individual disease pathways and require ongoing

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI businessThe divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunitiesUnder the terms of the agreement, RedHill obtain

Modern multipurpose marine instrument seamlessly integrates with other Garmin onboard electronics to keep mariners informed in real timeOLATHE, Kan., Sept. 1, 2026 /PRNewswire/ -- Garmin (NYSE:GRMN), the world's largest1 and most innovative marine electronics manufacturer, today unveiled the GMI™ 40 multipurpose marine instrument that displays live boating insights in an easy-to-read format. Boasting a modern, streamlined design that complements Garmin GPSMAP® chartplotters, the device has an intuitive touchscreen interface with edge-to-edge glass on a 4.3-inch, high-resolution, color LCD display. The touchscreen optimizes space for a clear, uninterrupted view of instrumentation data, keepin

FARMINGTON, Conn., Sept. 1, 2026 /PRNewswire/ -- Otis Worldwide Corporation (NYSE:OTIS) Chair, CEO & President Judy Marks will participate in a fireside chat at the 14th annual Laguna conference hosted by Morgan Stanley on Thursday, September 17, 2026, at 12:20 p.m. PT (3:20 p.m. ET). The fireside chat will be broadcast live at www.otis.com. About OtisOtis gives people freedom to connect and thrive in a taller, faster, smarter world. The global leader in the manufacture, installation, service and modernization of elevators and escalators, we move 2.5 billion people a day and maintain approximately 2.5 million customer units worldwide – the industry's largest Service portfolio. You'll find us

SAF production capacity expected to reach approximately 200 million gallon annual run rate by year-end 2028, with total renewable product sales expanded 40% to 17,000 barrels per dayRemaining project capital for this expansion reduced to $137 million from the $1.2 billion contemplated in the original Phase 2 plan, driven by the repurposing of proven equipment from the adjacent Calumet Montana Refining asphalt facility through a series of quick-payback stepsNo third-party equity requirement provides simple capital structure and eliminates dilution, positioning MRL for future strategic opportunities; expansion is expected to be funded with Montana Renewables earnings alongside a final $34 mill

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent DirectorIan Sheffield appointed to Invivyd’s Board of Directors as an independent directorDECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company. H

London, Ontario--(Newsfile Corp. - September 1, 2026) - VersaBank (TSX:VBNK) (NASDAQ:VBNK) (or the "Bank"), a North American leader in business-to-business digital banking, as well as technology solutions for cybersecurity, today announced that its recently launched Real-Time Structured Receivable Program (SRP) has been implemented for the first time in the United States by the Bank's SRP partner ECN Capital."As expected, there has been a flood of demand for our breakthrough Real-Time SRP from both existing and prospective partners since launch just a couple of months ago," said David Taylor, Founder and President, VersaBank. "Feedback from these partners continues to confirm the economic,

WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September:Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, September 8, 2026Fireside Chat Presentation Time: 3:45 p.m. E.T.Location: Boston, MACantor Global Healthcare Conference 2026Date: Wednesday, September 9, 2026Fireside Chat Presentation Time: 3:55 p.m. E.T.Location: New York, NYMorgan Stanley 24th Annual Global Healthcare ConferenceDate: Tuesday,

Versatile marine audio solution expands JL Audio M-series, providing remarkable sound and valueOLATHE, Kan., Sept. 1, 2026 /PRNewswire/ -- Garmin (NYSE:GRMN), the world's largest1 and most innovative marine electronics manufacturer, today announced JL Audio® M200 marine speakers and subwoofers, a stunning new audio series that blends a fresh design with high-performance sound to boost the onboard experience. Engineered to withstand harsh boating environments, the speakers are available in 6.5- and 7.7-inch sizes, offering clear, immersive sound, while the 10-inch subwoofer produces deep, powerful, clear bass. The M200 series speakers and subwoofers feature vibrant LED illumination in a wide

AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialize ZEGFROVY. ZEGFROVY is approved in the US and China for the 2nd-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Patients with NSCLC with EGFR exon 20 insertion mutations experience a real-world five-year overall survival rate as l

Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first candidate expected to enter clinical development in 2H 2027 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of pru

Multi-Million-Dollar Commercial Space Engagement Marks AEye’s Entry into the Space Mobility Market Expected to Scale Alongside the Push for a Permanent Human Presence on the Moon AEye, Inc. (NASDAQ:LIDR), a global leader in software-defined, high-performance lidar solutions, today announced that its Apollo™ long-range lidar has been selected by Lunar Outpost, the leader in space mobility and infrastructure, for integration onto the Pegasus Lunar Terrain Vehicle (LTV), which will transport Artemis astronauts across the lunar surface. The contract award further diversifies AEye’s commercial footprint beyond its core automotive, defense, and industrial markets into space mobility, a new mark

Rockwell Automation, Inc. (NYSE:ROK) Chairman & CEO, Blake Moret, and SVP, Intelligent Devices, Tessa Myers, will present at the Morgan Stanley 14th Annual Laguna Conference on Wednesday, Sept. 16, in Dana Point, California. The fireside chat will be webcast beginning at approximately 8:30 a.m. PDT and will be available on the Rockwell Automation Investor Relations website at www.rockwellautomation.com/en-us/investors.html. About Rockwell Automation Rockwell Automation, Inc. (NYSE:ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ETMorgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026 A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa’s website at ir.monterosatx.com, and arch

Bunge Global SA (NYSE:BG) announced today an agreement to sell its two sugarcane mills located in the municipalities of Junqueirópolis and Guararapes, in the state of São Paulo, Brazil, to COFCO International. The Rio Vermelho and Nova Unialco mills were formerly owned by Viterra and became part of Bunge upon the close of the business combination in July 2025. The completion of the transaction is subject to customary closing conditions, including the receipt of the necessary regulatory approvals. "As Bunge focuses on our strategic priorities and positions the business for long-term growth, this transaction is the right step forward. We are grateful to the sugar mills team for their dedi